291 related articles for article (PubMed ID: 28155606)
1. Clinical Utility of Neoadjuvant Endocrine Therapy for Hormone Receptor Positive Breast Cancer.
Kolberg HC; Aktas B; Liedtke C
Rev Recent Clin Trials; 2017; 12(2):67-72. PubMed ID: 28155606
[TBL] [Abstract][Full Text] [Related]
2. Using aromatase inhibitors in the neoadjuvant setting: evolution or revolution?
Freedman OC; Verma S; Clemons MJ
Cancer Treat Rev; 2005 Feb; 31(1):1-17. PubMed ID: 15707700
[TBL] [Abstract][Full Text] [Related]
3. Impact of combining the progesterone receptor and preoperative endocrine prognostic index (PEPI) as a prognostic factor after neoadjuvant endocrine therapy using aromatase inhibitors in postmenopausal ER positive and HER2 negative breast cancer.
Kurozumi S; Matsumoto H; Inoue K; Tozuka K; Hayashi Y; Kurosumi M; Oyama T; Fujii T; Horiguchi J; Kuwano H
PLoS One; 2018; 13(8):e0201846. PubMed ID: 30080878
[TBL] [Abstract][Full Text] [Related]
4. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer.
Jankowitz RC; McGuire KP; Davidson NE
Breast; 2013 Aug; 22 Suppl 2():S165-70. PubMed ID: 24074781
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant endocrine therapy in locally advanced estrogen or progesterone receptor-positive breast cancer: determining the optimal endocrine agent and treatment duration in postmenopausal women-a literature review and proposed guidelines.
Madigan LI; Dinh P; Graham JD
Breast Cancer Res; 2020 Jul; 22(1):77. PubMed ID: 32690069
[TBL] [Abstract][Full Text] [Related]
6. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant endocrine therapy: Patient selection, treatment duration and surrogate endpoints.
Yeo B; Dowsett M
Breast; 2015 Nov; 24 Suppl 2():S78-83. PubMed ID: 26255746
[TBL] [Abstract][Full Text] [Related]
8. [Neoadjuvant antihormonal treatment of women with breast cancer].
Tuxen MK; Kamby C; Nielsen DL
Ugeskr Laeger; 2007 Sep; 169(37):3077-81. PubMed ID: 17877952
[TBL] [Abstract][Full Text] [Related]
9. First-line endocrine therapy alone could be a reasonable treatment option for hormone-positive, HER2-positive metastatic breast cancer.
Peron J; Tredan O; Ray-Coquard I; Bachelot T; Labidi Galy SI; Favier B; Treilleux I; Guastalla JP
Bull Cancer; 2012 Feb; 99(2):E18-25. PubMed ID: 22257781
[TBL] [Abstract][Full Text] [Related]
10. Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies.
Brufsky AM
Cancer Treat Rev; 2017 Sep; 59():22-32. PubMed ID: 28719836
[TBL] [Abstract][Full Text] [Related]
11. Current advances in endocrine therapy options for premenopausal women with hormone receptor positive breast cancer.
Gemignani ML; Hetzel DJ
Gynecol Oncol; 2017 Oct; 147(1):153-157. PubMed ID: 28662774
[No Abstract] [Full Text] [Related]
12. Neoadjuvant use of endocrine therapy in breast cancer.
Macaskill EJ; Dixon JM
Breast J; 2007; 13(3):243-50. PubMed ID: 17461898
[TBL] [Abstract][Full Text] [Related]
13. One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
Rusz O; Vörös A; Varga Z; Kelemen G; Uhercsák G; Nikolényi A; Ormándi K; Simonka Z; Kahán Z
Pathol Oncol Res; 2015 Sep; 21(4):977-84. PubMed ID: 25753983
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
van Dam PA; van Dam VC; Altintas S; Papadimitriou K; Rolfo C; Trinh XB
Eur J Surg Oncol; 2016 Mar; 42(3):333-42. PubMed ID: 26776766
[TBL] [Abstract][Full Text] [Related]
15. Navigating the Challenges of Endocrine Treatments in Premenopausal Women with ER-Positive Early Breast Cancer.
Colleoni M; Munzone E
Drugs; 2015 Aug; 75(12):1311-21. PubMed ID: 26177891
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant endocrine therapy of breast cancer: which patients would benefit and what are the advantages?
Takei H; Kurosumi M; Yoshida T; Hayashi Y; Higuchi T; Uchida S; Ninomiya J; Oba H; Inoue K; Nagai S; Tabei T
Breast Cancer; 2011 Apr; 18(2):85-91. PubMed ID: 21104350
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant endocrine therapy for postmenopausal patients with hormone receptor-positive early breast cancer: a new concept.
Iwata H
Breast Cancer; 2011 Apr; 18(2):92-7. PubMed ID: 21140250
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant endocrine treatment in breast cancer: analysis of daily practice in large cancer center to facilitate decision making.
Debled M; Auxepaules G; de Lara CT; Garbay D; Brouste V; Bussières E; Mauriac L; MacGrogan G
Am J Surg; 2014 Nov; 208(5):756-763. PubMed ID: 24814311
[TBL] [Abstract][Full Text] [Related]
20. Management of Premenopausal Women with Neoadjuvant Endocrine Therapy: A Single-Institution Experience.
Barbie TU; Ma C; Margenthaler JA
Ann Surg Oncol; 2015 Nov; 22(12):3861-5. PubMed ID: 25783678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
